Allergan's Ozurdex steroid-eluting implant fared better than a control group in improving best corrected visual acuity in pseudophakic patients with diabetic macular edema at three years, data from the Macular Edema Assessment of Implantable Dexamethasone in Diabetes indicated. However, more phakic DME patients in the Ozurdex arm developed cataract or lens opacity than those in the non-treatment cohort.

Related Summaries